|1.||Morissette, Marc: 5 articles (04/2010 - 01/2006)|
|2.||Di Paolo, Thérèse: 5 articles (04/2010 - 01/2006)|
|3.||Hadj Tahar, Abdallah: 4 articles (04/2010 - 03/2004)|
|4.||Samadi, Pershia: 3 articles (04/2010 - 06/2009)|
|5.||Grégoire, Laurent: 3 articles (01/2010 - 03/2004)|
|6.||Meltzer, Leonard T: 3 articles (06/2009 - 01/2006)|
|7.||Dridi, Mehdi: 3 articles (06/2009 - 01/2006)|
|8.||Bédard, Paul J: 3 articles (09/2006 - 03/2004)|
|9.||Bélanger, Nancy: 2 articles (04/2010 - 03/2004)|
|10.||Ouattara, Bazoumana: 2 articles (01/2010 - 06/2009)|
03/01/2004 - "Acute treatment with CI-1041 did not provide any notable protection against secondarily generalized seizures. "
03/01/2004 - "The present study was designed to assess the effects of CGX-1007 and CI-1041 on the acquisition and expression of kindled seizures. "
03/01/2004 - "Although both CI-1041 and CGX-1007 are reportedly NR2B specific antagonists, they differ in their ability to block amygdala-kindled seizures, suggesting that the mechanism of action of these compounds differs. "
03/01/2004 - "In the corneal kindled rat, CGX-1007 [Epilepsia 36 (1998) 39] and CI-1041, administered p.o., 2h prior to the kindling stimulation displayed time- and dose-dependent block of fully expressed corneal kindled seizures (ED50 = 300 pmol and 2.5mg/kg for CGX-1007 and CI-1041, respectively). "
03/01/2004 - "CI-1041 co-treatment completely prevented the induction of dyskinesias in three animals and only one monkey developed mild dyskinesias at the end of the fourth week of treatment in the L-dopa + CI-1041 group. "
01/01/2006 - "These findings suggest that chronic blockade of striatal NR1A/2B NMDA receptors with CI-1041 normalizes PPE-A mRNA expression and prevents the development of LD-induced dyskinesias in an animal model of Parkinson disease."
01/01/2006 - "The present study investigated the effect of chronic treatment with a selective NR1A/2B N-methyl-D-aspartate (NMDA) receptor antagonist, CI-1041, on the expression of preproenkephalin-A (PPE-A) in brains of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) -treated monkeys in relation to the development of LD-induced dyskinesias. "
09/01/2006 - "Four MPTP monkeys received L-DOPA/benserazide and all developed dyskinesias, whereas among the four MPTP monkeys who additionally received CI-1041, only one developed mild dyskinesias. "
04/16/2010 - "The present experiment investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkeys, the effects on Akt/GSK3 of chronic L-Dopa treatment inducing dyskinesias compared to L-Dopa with CI-1041 (NMDA receptor antagonist) or a low dose of cabergoline (dopamine D2 receptor agonist) preventing dyskinesias. "
|3.||Parkinson Disease (Parkinson's Disease)
|1.||1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
|5.||Levodopa (L Dopa)
|6.||N-Methyl-D-Aspartate Receptors (NMDA Receptors)
|10.||Kynurenine 3-Monooxygenase (Kynurenine 3 Monooxygenase)